These results suggest that DPP-4 inhibitors reduce the risk of major adverse cardiovascular events compared to diabetes drugs (with the exception of SGLT2 inhibitors which can also be used to treat chronic heart failure) and placebo [26,27,28]. This evidence concerns the gene SLC5A2 and congestive heart failure.